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Abstract 
AIM: The purpose of this clinical trial was to investigate the analgesic efficacy 
of four oral medication groups on postoperative endodontic pain after first stage 
root canal treatment.  The four groups will be  
Methodology: Patients presenting to the University of Minnesota emergency 
graduate endodontic clinic experiencing pain greater than or equal to 3/10 were 
considered potential condidiates.  22 patients were included based on an estab-
lished inclusion criteria.  Following administration of local anaestheisa, a pulpec-
tomy was performed.  The patients were administered the following at 4 hour 
time intervals: (1) 2 doses of Placebo; (2) 2 800mg doses of Ibuprofen; (3) 2 
800mg Ibuprofen with Vicodin 325/7.5mg; (4) 1 dose of 550mg Anaprox DS 
(Naproxen) and 1 dose of Placebo.  Patients recorded pain intensity following 
treatment on a visual analogue scale, Heft parker scale and a baseline four-point 
category pain scale before and immediately after treatment, then one hour after 
the initial dose of medication, and one hour after the second dose of medication.  
The following day, pain was recorded at breakfast, lunch, dinner and bedtime. 
Results:  At about 24 hours, 27% had moderate to severe pain.  All patients 
showed significant pain reduction after initial root canal therapy.  The ibuprofen 
group showed a rebound in pain the following day.  Males had more rebound 
pain compared to females.  Anaprox DS and the  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combination of Ibuprofen and Vicodin showed the most pain reduction at all 
time periods.  In our study, the results suggested that pulp vitality had little effect 
on post operative pain.   
Conclusion: Primary endodontic treatment will greatly decrease the pain felt by 
the patient.  High doses of Ibuprofen followed by an abrupt stop might lead to a 
rebound in pain.  Tooth vitality did not seem to affect post operative discomfort, 
nor did patient gender.  More research using this model and analgesic combina-
tion is necessary to ensure statistically significant results. 
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A COMPARISON OF PHARMACEUTICAL REGI-
MENS FOLLOWING FIRST STAGE ROOT CANAL 
TREATMENT 
 Pain is defined as an unpleasant sensory and emotional experi-
ence associated with potential or actual tissue damage (International 
Association for the Study of Pain 1994).  Dental pain in general and 
toothache pain specifically is one of the key predictor of patients seek-
ing dental treatment (Locker and Grushka 1987), other than regularly 
scheduled check-ups.  Dental pain has been shown to occur quite fre-
quently, with nearly 15 percent of adults in the United States experi-
encing toothache, oral sores, jaw joint pain, facial pain, or burning 
mouth in a six month period (Lipton et al 1993).  These rates were 
comparable to rates seen in the United Kingdom and Canada (Shepard 
et al 1999, Locker and Grushka 1987).  Dental pain can interfere great-
ly in the patient's life, making sleep and work nearly impossible.  Every 
year in the United States approximately 15 million working days are 
lost due to dental pain (Taylor and Curran 1985). 
 One of the main objectives of endodontic therapy is to alleviate 
these patients from pain.  Continued pain between appointments can be 
a considerable problem for patients and endodontists alike.  Despite 
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many advances in the field, the incidence of mild inter appointment 
pain has been reported up to 30 percent of the time and 15.7 percent for 
severe pain (Harrison et al 1983).  Postoperative pain was more likely 
to occur in these patients within the first twenty four hour period fol-
lowing treatment (Harrison et al 1983).  Patients presenting with ex-
treme preoperative levels of pain were more likely to have a similar 
degree of pain both operatively and postoperatively (O’Keef 1976).  
Thus, it is critical for the clinician to minimize or prevent pain by fol-
lowing appropriate treatment regimens supplemented with analgesics 
where indicated (Menhinick et al 2004). 
 Even with many advances in endodontic therapy and an in-
creased knowledge of pulpal morphology, histology and immunology, 
a large percentage of patients still report pain after endodontic treat-
ment.   Seltzer and Bender in 1961 found a 40% incidence of post op-
erative pain among 698 patients.  Georgopoulou in 1986 had similar 
findings, with 43% of the 245 patients experiencing pain after en-
dodontic treatment.  Numerous studies have shown that this pain fol-
lowing treatment is usually the highest the first 24 hours post treatment 
(Harrison et al, 1983, Liesinger et al, 1993, Marshall and Liesinger 
1993, Torabinejad et al 1994). 
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 There are numerous etiologic factors associated with odontalgia, 
but tooth pain is usually caused by either noxious physical stimuli, or a 
release of inflammatory mediators that stimulate terminal endings of 
afferent nerve fibers (Chiu et al 2012).  A release of inflammatory me-
diators such as prostaglandins, leukotrienes, bradykinin and serotonin 
activates sensitive nociceptors surrounding the tooth, and is thought to 
be the major cause of pain (Menhinick et al 2004, Johnsen et al 1983).  
This leads to both the central and peripheral mechanisms of hyperala-
gesia which will increase the perceived magnitude of a painful stimulus 
(Dubner and Bennet 1983).  These processes can be controlled through 
root canal treatment and or the use of anti-inflammatory agents (Men-
hinick et al 2004).  One such medication is acetaminophen whose 
mechanism of action is not fully understood.  However it is known that 
it is a weak inhibitor of peripheral prostaglandin synthesis (Bjorkman 
et al 1994).  Acetaminophen is also known to be in some way active in 
the central nervous system via the inhibition of central hyperalgesia 
induced by pain producing neurotransmitters (Aminoshariae and Khan 
2015, Bjorkman et al 1994).   
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 Ibuprofen is one of the most commonly used non-steroidal anti-
inflammatory drugs (NSAID) (Menhinick et al 2004, Cooper et al 
1993).  These drugs inhibit prostaglandin synthesis by decreasing the 
activity of cyclo-oxygenase enzymes (COX) which exists in two 
isofroms COX 1 and COX 2.  COX 2 is released with tissue injury, 
which is induced rapidly, (in 1-3 hours) and can be detected in high 
concentrations in macrophages, monocytes, leukocytes in response to 
mediators of inflammation (Cooper et al 1993, Arslan et al 2011).  Hy-
drocodone is an opioid used for analgesic, antitussive, antihyperten-
sive, sedative and hypnotic properties.  It is metabolized in the liver 
into it’s primary active compounds morphine and codeine-6-glu-
curonide, where it then binds to u-opioid receptors (Morse et al 1987, 
Garoulis et al 2012).  The combination of acetaminophen and an 
NSAID has demonstrated improved pain control compared with either 
drug used separately in the literature for patients with various pulpal 
conditions (Menhinick et al 2004).   There have been no controlled 
dental studies that make the comparison between the combination of 
hydrocodeine/acetaminophen with ibuprofen, ibuprofen alone and or 
naproxen alone.   
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 The purpose of this clinical trial is to investigate the analgesic 
efficacy of four oral medication groups on postoperative endodontic 
pain after local anesthesia with either lidocaine 2% with epinephrine 
1:100000 or a long acting local anesthetic (bupivacaine 0.5% with epi-
nephring 1:200000).  The four drug groups include a lactose placebo, 
800 mg ibuprofen, Anaprox DS (550 mg naproxyn sodium), or aceta-
minophen/hydrocodone (Vicodin 325 mg/7.5 mg).  The difference in 
postoperative analgesic efficacy will be measured using the VAS (100 
mm scale), Heft-Parker (170 mm scale with descriptors) , and Categor-
ical  (no pain, mild pain, moderate pain, severe pain) pain scales over 
36 hours.  
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HYPOTHESES: 
 The null hypothesis of this research project is that there will be 
no difference between the groups in pain control.  That is, the root 
canal intervention alone will be enough for pain relief.  The Alternate 
hypothesis is that there will be a significant decrease in the level of 
pain between the placebo group versus medicated groups.  Further-
more, there will be a difference between the different drug groups.  
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MATERIALS AND METHODS: 
 This study was approved by the University of Minnesota Insti-
tutional Review Board (IRB).  Patients were selected from those that 
presented to the University of Minnesota College of Dentistry’s urgent 
care clinic.  Potential candidates presented with moderate to severe 
spontaneous pain of odontogenic origin with a rating of 3 or higher on 
a 10 point scale.  Following assignment to a graduate endodontic resi-
dent, the patients were given further information about the study, and 
strict inclusion criteria was applied.    Inclusion criteria will be; 
1. Patient greater than 18 years of age but less than 65 
2. No pain medication taken within the last 4 hours.   
3. No allergy to NSAIDS, acetaminophen or local anesthetics 
4. No gastrointestinal or kidney disorders 
5. Spontaneous pain >3 on a 10 point scale 
6. Patient requires a root canal treatment 
7. Patient has an American Society of Anesthesiologists (ASA) I or II 
medical history 
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8. Patient has given informed consent.   
9.Patients are not pregnant. 
10. No history of opioid abuse. 
 Patients were divided based on the type of local anaesthesia 
used; either two carpules of 2% Lidocaine with epinephrine 1:100,000  
3.4 ml, or two carpule of a long acting local anesthesia, 0.5% Bupiva-
caine with epinephrine 1:200,000 3.6 ml.  The treating dentist could 
also use one additional carpule of Lidocaine, despite the group, should 
it be necessary.  If local anaesthesia is not obtained at this point, the 
patient will be eliminated from the study, and given additional local 
anaesthesia to complete the treatment. 
Patients will be further subdivided into the following drug groups: 
1.Anaprox DS (naproxyn sodium) 1st dose, Placebo 2nd dose 
2.Placebo 1st dose, placebo 2nd dose 
3.Ibuprofen 800mg 1st dose, Ibuprofen 800 mg 2nd dose 
4.(Ibuprofen 800 mg + Vicodin(acetaminophen/hydrocodone) 1st dose, 
(Ibuprofen 800 mg + Vicodin) 2nd dose 
  
 Patients consenting to be in the study were given local anaes-
thetic that had been previously randomized with label covered and pro-
vided within the patient packet for the treating dentist.  Pain evaluation 
forms were also be provided in the packet.  Standardized endodontic 
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procedures were performed by the graduate endodontic residents under 
rubber dam isolation.  Resident used rotary nickel titanium instruments 
in a modified crown-down technique and stainless steel hand instru-
ments as necessary.  The cleaning and shaping was done to at least a 
size 25 master apical file to within 0.5 - 1.0mm of the estimated work-
ing length determined by apex locators and verified by radiographs.  
Copious irrigation with 5.25% sodium hypochlorite was used between 
each file.  Once instrumentation was completed, the canals were dried 
with paper points, and an intra-canal medicament of Calcium Hydrox-
ide (UltraCal X5, Ultradent USA) and a cotton pellet was placed in the 
access cavity, which was then restored with 3mm of Cavit.   
 When the patient neared completion of the endodontic treat-
ment, a prescription written for the IRB study and was presented to the  
pharmacy, which will then fill the prescription with a randomized code 
known only to the Investigational Drug Services (IDS) pharmacy at the 
UMN.  Two clear, unmarked, indistinguishable vials were provided by 
the pharmacy for each patient labelled “1st dose” and “2nd dose”.  The 
first dose was taken 1 hour after dental treatment had been completed 
when the patient is safe at home, and the 2nd dose 4 hours later.  The 
vials contained the appropriate randomized drugs from the drug groups 
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above in the generic form.  The IDS pharmacy provided a 24 hour, 7 
day a week phone service number if the patients experienced pain that 
was not managed by the test drug.  The patient would have been un-
blinded, and given the appropriate rescue medication.   
 Also provided in the packet was a pain diary that contained two 
pain scales (VAS and Heft-Parker scale) and a categorical scale which 
was simply descriptive of the pain intensity on a four point scale from 
“no pain” to “severe pain.  There was an area for the patient to record 
any side-effects.  The diary was 8 pages long, designed so patients can 
make entries pre-treatment, immediately post treatment, then 1 hour 
following the 1st dose of medication, 1 hour following the second dose 
(6 hours later), and then the following day at breakfast, lunch, dinner 
and bedtime.  Had any medication been taken the following day, the 
patient had a place to indicate which medication taken, and the dose.   
To compare treatment groups without considering initial VAS, a re-
peated measures analysis of variance was used, where the random ef-
fect is subject and the fixed effects are drug, group and time, and their 
interaction.  To compare treatment groups while also considering initial 
pain scale, a mixed linear model was used, a generalization of a repeat-
ed-measures ANOVA.  If group by time interaction is significant, sepa-
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rate post-hoc tests will be done comparing the medication groups at 
each time point. 
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Literature Review 
 Dental pain is one of the leading causes of people seeking den-
tal treatment, with 12% of Americans suffering with odontalgia annual-
ly (Anderson and Thomas 2003; Gilbert et al 2003).  Approximately 
85% of all dental emergencies arise as a result of pulpal or periapical 
disease, which would necessitate either extraction or endodontic treat-
ment to relieve pain (Hasler and Mitchel 1963).  Awareness of pain in-
volves its detection, which is a function of the peripheral sensory neu-
rons, then the processing which involves the selective activation of 
specific and related central nervous system pathways that are depen-
dent on initial processing done with the medullary and spinal dorsal 
horns.  The final step of pain awareness is perception, which is the re-
sult of activity in the more rostral brain regions such as the cerebral 
cortex  (Hargreaves 2013).  All three of these steps are responsible for 
the multidimensional aspect of pain that includes pain both as a sensa-
tion and emotion for the patient.  For clinicians, the initial challenge is 
to understand the biological process resulting in pain.  
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 The pulp is one of the most densely innervated tissues in the 
body, containing both sensory afferent fibres and sympathetic fibers 
that modulate blood flow (Trowbridge 1986).  The sensory and post-
ganglionic sympathetic nerves that innervate the dental pulp originate 
in the trigeminal and superior cervical ganglia, respectively, and enter 
through the apical foramen.  The nerve bundles pass coronally through 
the radicular pulp along with blood vessels, fanning out once reaching 
the cell-rich zone of the pulp.  Nerves are classified based on their di-
ameter, conduction velocity and function (Itoh 1979, Johnsen 1985).  
In the pulp, we find two types of sensory nerve fibers; the myelinated 
(A fibers) and the unmylinated (C fibers).  The A fibers consist mainly 
of the A beta and A delta fibers.  The A beta fibers are larger, and have 
faster conduction velocity when compared with the A delta fibres.  Ap-
proximately 90% of the mylenated fibers are A delta (Olgart 1989).   
Branches of the nerves will give rise to the network called the sub-
odontic plexus in the peripheries of the pulp, where the fibres terminate 
as free nerve endings (Trowbridge 1986).  These free nerve endings 
will pass between the odontoblast cell bodies and enter the dentinal 
tubules (Byres et al 1980).  These intratubular nerve endings are most 
numerous in the pulp horn, where nearly 40% of tubules will contain 
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nerve fibres (Byres 1984).  Intradental A and C fiber groups are func-
tionally different and can be activated separately by certain external 
stimuli with A fibers responsible for the sensitivity of dentine and the 
mediation of sharp pain brought on by light stimulation (Narhi et al 
1992, Olgart et al 1989, Nair 1995).  Intradental C fibers are activated 
only if the external stimuli is able to reach the pulp proper.  Their acti-
vation may contribute to the dull pain induced by intense thermal stim-
ulation, or that associated with pulpal inflammation.  In the pulp prop-
er, only C fibres can be activated by histamine and bradykinin seen in 
inflammation (Narhi et al 1992). 
 Inflammation seen in diseased dental pulps leads to the activa-
tion of pulpal nociceptors and odontogenic pain (Woolf 1999, Willis 
1985, Hargreaves et al 2001).  This pain is thought to arise from the 
activation of unmyelinated nociceptors due to the distribution of C 
fibers in the dental pulp, their responsiveness to inflammatory media-
tors, and similar perceptual qualities of pain associated with C fiber 
activation (Hargreaves 2013, Ahlquist et al 1985).  Stimuli will cause 
depolarization of nociceptors sufficient to generate an action potential 
by means of opening voltage gated sodium channels.  The information 
from this action potential will be sent not only to the central nervous 
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system, but will also be sent in the reverse direction back into the tissue 
antidromically (Keiser and Byrner 2011).  This is also referred to as 
axon reflex, and will stimulate the release of pro inflammatory neu-
ropeptides such as substance P (SP), calcitonin gene-related peptide 
(CGRP) from the pulpal nerve fibers (Hargreaves and Swift 1993).  
CGRP has been shown to cause vasodilation, while SP increases vascu-
lar permeability acting directly on arterioles and venules, and indirectly 
stimulates the release of histamine and eiconsanoid production by mast 
cells.  The levels of substance P in pulp tissues diagnosed with irre-
versible pulpits are seen to be increased eight fold (Bowles et al. 2003).  
Prostaglandin, which is produced after the release of eiconsanoid has 
been shown to be present in higher concentrations in acute periradicu-
lar lesions of inflamed teeth (McNicholas et al. 1991) as well as sub-
stantially increasing the stimulatory effect of bradykinin (Goodis et al 
2000). 
 The action potential is propagated along a peripheral trigeminal 
nerve to the primary afferent neuronal cell body located in the trigemi-
nal ganglion, and then into the central nervous system (Hargreaves et al 
2001).  Impulses carried by the trigeminal nerve will enter directly into 
the brain stem in the region of the pons to synapse with the second or-
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der neurons in the trigeminal spinal nucleus.  This region is structurally 
very similar to the dorsal horn of the spinal cord, and is sometimes re-
ferred to as the medullary dorsal horn. The caudal extent of the trigem-
inal nucleus will merge with the dorsal horn at the upper cervical level 
(Hargreaves and Goodis 2001).  
 The trigeminal spinal tract nucleus is divided into three regions; 
the subnucleus oralis, subnucleus interpolaris and the subnucleus cau-
dalis.  Primary afferent neurons innervating dental pulp terminate in all 
the different subnuclei located within the ipsilateral trigeminal sensory 
nucleus, including prominent projections to the subnucleus caudalis 
(Sjoqvist 1938).  The caudal region plays a critical role in the modula-
tion and transmission of nociceptive information from the trigeminal 
sensory nucleus.  The impulse is then carried by the second order neu-
rons across the brain stem to the anterolateral spinothalamic pathway 
and ascends through the reticular formation to the thalamus.  The retic-
ular formation will control the overall activity of the brain by either 
enhancing or inhibiting the impulses to the brain.  The impulse will fi-
nally ascend to the cortex for interpretation and evaluation.  Output to 
higher brain regions can be increased, decreased or misinterpreted from 
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incoming activity (Okeson 1995, Malamed 1990, Henry and Harg-
reaves 2007).   
'  
Figure 1: Graphic illustration of the convergent effect of nocicep-
tive input on the trigeminal spinal trac nucleus.  The C3 will con-
verge on the trigeminal neuron, creating nociceptive input ascend-
ing onto the higher centres. (Henry and Hargreaves 2007) 
 For many years, it was suggested that there is a circuit system in 
the CNS that can modulate incoming pain information.  The first pain 
modulatory mechanism, called the ‘Gate Control theory’ was proposed 
by Melzack and Wall.  The concept is that non-painful input closes the 
gates to painful input, thus preventing pain sensation travelling to the 
CNS (Melzac and Wall 1964).  It is now accepted that there is a power-
ful inhibition of pain-related information in the spinal cord.  Circuit 
interneurons are an important part of the trigeminal sensory nuclei as 
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they will ultimately regulate the transmission of nociception signals 
from the primary afferent fibers to projection neurons (Hargreaves 
2012).  Inhibitory influences are provided by GABA or opioid within 
the synaptic vesicles located in the primary afferent axon terminals at 
axoaxonic inhibitory synapses, providing presynaptic inhibition of 
primary afferent input (Hargreaves 2002).  Another integral part of the 
trigeminal sensory nuclei are the descending neurons which modulate 
the transmission of nociceptive information within the other caudal 
neural components via endogenous opioids and serotonin (Millan 
2002, Hargreaves 2012).  The analgesic action of some selective sero-
tonin reuptake inhibitors and opioids may involve activation of these 
descending neurons (Hargreaves 2012).  Endogenous opioid peptides 
possess many of the properties of exogenous opioids such as morphine 
and codeine, and are found at several levels of pain suppression system 
(Hargreaves et al 1986).  Endogenous cannabinoid system is another 
modulatory system that can inhibit the central terminals of C fibres.  
There are ten times more cannabinoid receptors than opioid in the CNS 
(Hohmann and Herkenham 1999) and cannabinoid receptors in the 
pulp which act to inhibit peripheral terminals of unmyelinated nocicep-
tors (Hohmann and Herkenham 1999). 
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 Microbial infections are the most prevalent aetiology of pulpal 
inflammation followed by trauma (Hargreaves 2012).  Inflammation 
evoked by microorganisms is a complex response that involves recog-
nition of antigenic molecular patterns, and the coordinated release of 
multiple classes of inflammatory mediators such as bradykinin, IL1 
and PGE2 to name a few  (Hargreaves and Hutter 2002).  Lipopolysac-
charide (LPS) is the most prominent microbial antigen in dental infec-
tions due to the high representation of gram negative bacteria (Hashio-
ka et al 1992, Siqueira et al 2004).  LPS has the ability to diffusing and 
reaching the pulp faster than bacteria (Khabbaz et al 2001), thus alert-
ing of the host of incoming bacterial infection quite early.  Vasoactive 
peptides such as CGRP and SP will initiate and amplify the pulpal in-
flammatory reaction, also known as neurogenic inflammation.  These 
peptides will act in conjunction with the aforementioned cytokines re-
leased by dendritic cells to activate the innate immune response by 
specific receptors expressed on the plasma membrane of cells of innate 
immune response, namely the toll-like receptors 4 (TLR4) (Diogenes et 
al 2011).  TLR4 is also expressed in dental nociceptors and neuronal 
recognition of this bacterial component activates and sensitizes these 
dental pain sensing fibres, thus increasing nociceptive signals and re-
lease of pro inflammatory neuropeptides (Diogenes et al 2011, Ferraz 
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et al 2011).   Primary afferent terminals in the dental pulp and peri-
radicular tissues can directly sense the bacterial presence by the activa-
tion of TLR4 and subsequent activation of it’s associated nociceptors, 
leading to an alerting pain signal and activation of the immune defence 
(Jiang et al 2006).   
 The earliest pulpal response to bacterial infection or antigens 
includes the infiltration of polymorphonuclear leukocytes (PMNs) and 
monocytes, with PMN’s being the most abundant type of phagocytes 
(Bergenholtz and Lindhe 1975, Takahashi 1998).  In PMNs and reticu-
locytes, arachidonic acid is metabolized by the lipooxygenase enzyme 
to produce a series of products called leukotrienes.  Leukotrienes have 
been found to be potent chemotactic and enzyme-releasing agents for 
leukocytes, and have been associated with smooth muscle constriction 
and broncho-constriction (Samuelsson and Hammarstrom 1980).  
Leukotrienes have also been shown to have 100-1000 times the power 
of prostaglandins and histamine in promoting vasodilation and vascular 
permeability (Samuelsson 1983).  In addition to the pro-inflammatory 
actions of leukotrienes (chemotaxis, vasodilation, and vascular perme-
ability), this family of  
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compounds has been shown to prolong the excitation of neurons 
brought about by the aforementioned neurogenic inflammation, thus 
possibly reducing pain threshold (Madison et al 1992).   
 
Figure 2: Schematic Representation of the 5-Lipoxygenase enzyme metabolic 
pathway. 
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Figure 3: The Eoicasanoid Synthetic Pathway 
 Cyclooxyrgenase (COX) is an enzyme that is responsible for the 
formation of prostanoids, such as prostaglandins and thromboxane.  
Two of the most common types of COX enzymes are COX-1 which is 
present in most tissues and COX-2 which is found primarily at sites of 
inflammation.   The COX-1 enzyme is distributed throughout the body 
and produces prostaglandins which have a protective role that includes 
preventing gastrointestinal ulcers, regulating platelet action, and con-
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tribute to kidney function.  Prostacyclin and PGE2 reduce gastric acid 
secretion, exert direct vasodilator action on the vessels of the gastric 
mucosa, and stimulate the secretion of viscous mucous as a protective 
barrier against gastric ulcers.  In platelets, COX-1 activity produces 
TXA2, causing aggregation of the platelets and prevention of inappro-
priate bleeding.  PGE2 and PGI2  promote vasodilation in the kidney, 
thus preventing kidney ischaemia.  PGE2 also inhibits reabsorption of 
sodium and chloride from the ascending loop of Henle in the kidney, 
and attenuates reabsorption of sodium by vasopressin in the collecting 
ducts, thus increasing urine flow (Vane and Botting 1998).  COX-2 is 
an inducible enzyme that increases in inflammation.  Byproducts in-
clude prostaglandins in migratory and resting cells.  Little or no COX-2 
is found in resting cells, but expression can be increased by exposure 
of these cells to bacterial lipopolysaccharides or cytokines during in-
flammation (Vane and Botting 1998). 
 Hyperalgesia, an increase in the perceived magnitude of painful 
stimuli, can develop in response to changes in the pain system.  These 
changes can be seen within seconds of the appropriate stimuli (Harg-
reaves et al 2001, Sessle 2000).  Hyperalgesia occurs not only in areas 
of inflammation and tissue injury (Primary hyperalgesia), but also in 
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adjacent areas (Secondary hyperalgesia) (Raja et al 1984).  Allodynia, a 
reduction in the pain threshold so that previously non-noxious stimuli 
are perceived painful, can also arise from these changes in the pain sys-
tem (Pacheco et al 2011).  In a recent prospective study, mechanical 
allodynia was detected in 56% of those diagnosed with necrotic pulps, 
and 67% of those with irreversible pulpits (Olgart et al 1989).  Central 
mechanisms of allodynia and hyperalgesia have been proposed, and 
can lead to a pain state called central sensitization, marked by an in-
creased excitability of central neurons (Woolfe 1996).  Activation of 
pulpal neurons produces central sensitization due to the release of glu-
tamate and SP, and an increased expression of NMDA receptors in both 
the trigeminal nuclei and thalamus (Chiang et al 1998, Sunakawa et al 
1999).  Allodynia and hyperalgesia can persist after the removal of the 
sensory input from inflamed tissue, which can explain why up to 80% 
of patients who experience pain before endodontic treatment will re-
port pain after (Marshall and Walton 1984, Marshall and Liesinger 
1993).  Patients with moderate or severe pain usually report greater 
pain levels for 3 days after endodontic treatment  (Hargreaves KM et al 
2002).  It has been recently reported that the overall incidence of pain 
six months post endodontic treatment is 5.3% with 3.4% of nonodon-
togenic origin (Nixdorf et al 2010).  
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 It is impossible to provide effective dental care without the use 
of local anaesthetics.  These drugs interrupt neural conduction by in-
hibiting the influx of sodium ions after diffusing through the neural 
membrane and enter sodium channels, preventing them from assuming 
the open “active” state (Becker and Reed 2006).   Thus, the resting po-
tential of the nerve is altered which alters the threshold potential at 
which the nerve will fire, decreasing the rate of depolarisation, and 
prolonging the repolarization phase.   There are two different families 
of local anaestehtics, defined by the chemical linkages between the 
groups; those with esther and those with amide linkages.  The amide 
linkages are more popular and in wider use due to issues with allergies 
seen in the esther anaesthetics (Becker and Reed, 2006).  Local anaes-
thetics have pKas that range between 7.5 to 8.1 thus making them weak 
bases (Malamed et al 2012). The onset and duration of local anaesthet-
ics are highly variable and specific for each drug, and affected by a 
number of factors.  The most significant of these factors being the pKa, 
pH of the solution, lipid solubility, the concentration of active ingredi-
ent of the drug and the use of vasoconstrictors such as epinephrine 
(Malamed et al 2012).  Two common local anaesthetics used are 
bupivicaine and lidocaine.  Bupivicaine is much more lipid soluble 
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compared to lidocaine, thus it is more potent and necessitating a lower 
concentration (0.5% versus 2.0%).  Bupivicaine also has greater pro-
tein binding, and thus longer duration  versus lidocaine (Bacsik et al 
1995).  When comparing the long acting bupivicaine anaesthetic with 
the moderately acting lidocaine, Moore and Dunsky found no differ-
ence in the onset and profundity of anaesthsia.  It was discovered, 
however, that there was a significant decrease in postoperative pain in 
the bupivicaine group (Moore and Dunsky 1983). 
 Many studies have shown the efficacy of definitive dental 
treatment, such as pulpotomies, pulpectomies, occlusal adjustment and 
trephination to reduce acute pain.  Pulpotomies, the removal of the 
coronal portion of a vital pulp as a means of preserving vitality, have 
been shown to reduce pain symptoms in 88% of patients 24 hours after 
the initiation of treatment (Hasselgren et al 1989).  Pulp debridement, 
the complete removal of the pulp tissue, is the treatment of choice with 
symptomatic irreversible pulpitis or with necrotic tissue (Doroschak et 
al 1999, Torabinejad et al 1994, Hasselgren 1989).   Pak and White 
found that one week after endodontic treatment, only 5% still experi-
enced pain, but normally at a substantially minimal level (Pak and 
White 2011).  Preoperative occlusal adjustment has been shown to help 
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reduce reduced patient pain on biting (Jostes et al 1984), but has little 
effect on postoperative pain (Parirokh et al 2013, Creech et al 1984).  
An in vivo study demonstrated that patients presenting with pain, per-
cussion sensitivity, vital pulps and no periradicular radiolucencies 
would benefit the most from occlusal reduction (Rosenberg et al 1998).   
Other forms of definitive treatment to decrease pain are incision and 
drainage and trephination which help reduce tissue pressure.  However 
trephination, a surgical procedure in which there is a perforation of the 
alveolar cortical plate, has been suggested to have questionable post 
operative benefit, and might add to the discomfort (Moos et al 1996, 
Houck et al 2000).  The pain relieving benefits of all the aforemen-
tioned treatments are believed to be based on reduction in tissue levels 
of factors that stimulate peripheral terminals of nociceptors or reduce 
the mechanical stimulation of sensitized nociceptors.  These treatments 
can provide a predictable pain reduction in patients with an endodontic 
emergency (Doroschak et al 1999).  
 Even when endodontic procedures are performed to the highest 
standard, the patient can still suffer with post-operative pain, with up to 
40% of patients still experiencing post-treatment pain during the first 
24 hours (Harrison et al 1983, Moskow et al 1984, Georgopoulou et al 
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1986, Oguntebi et al 1992, Liesinger et al 1993, Marshall and Liesinger 
1993, Torabinejad et al 1994, Mattscheck et al 2001, Direnzo et al 
2002).  Pre-treatment and post-treatment endodontic pain is thought to 
be related to a periapical inflammatory response.  Inflammatory media-
tors from the infected pulp are thought to cause irritation and sensitiza-
tion of periapical tissue (O’Keefe 1976, Harrison et al 1983, Marshall 
and Liesinger 1984, Genet et al 1987, Torabinejad et al 1988, Walton 
and Fouad 1992, Torabinejad et al 1994, Mattscheck et al 2001).  
 There have been many factors in the literature that are linked 
with post-operative pain following a non-surgical root canal treatment.  
One of the major predictors of post-treatment endodontic pain is the 
presence and duration of pre-treatment pain or swelling (O’Keefe 
1976, Harrison et al 1983, Walton and Fouad 1992, Mattcheck et al 
2001, Ng et al 2006).  Patients that had previously experienced painful 
treatment in the orofacial region were approximately 3.8 times more 
likely to have pain after a root canal treatment (Polycarpou et al 2005).  
Molar teeth have been implicated also, especially if in the mandible 
(Walton and Fouad 1992, Ng et al 2006).  Studies have been contra-
dicting when considering preoperative tooth vitality as a factor, with 
some suggesting there is greater discomfort in necrotic teeth (Walton 
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and Fouad 1992) and others suggesting that pulpal diagnosis has no 
significance, especially if apical patency is maintained (Arias et al 
2009).  Some studies found that females were much more likely than 
men to develop post operative pain (Torabinejad et al 1988, Ng et al 
2004, Polycarpou et al 2005).  However, other studies did no find gen-
der differences in prevalence, and suggested that those studies that did 
were biased as ladies were more likely to keep an appointment for pain 
(Locker and Grushka 1987, MacEntee et al 1993).  Post-treatment pain 
can occur in response to instrumentation and extruded bacteria/necrotic 
tissue (Seltzer and Naidorf 1985, Torabinejad et al 1988, Siqueira et al 
2004).   While pain levels tend to diminish after 24 hours, it is perfectly 
understandable for a patient to desire minimal to no pain during and 
after treatment.  To aid in the control of post-treatment pain, an anal-
gesic agent or a combination of anti-inflammatory/analgesic agents can 
be used.  Thus, it is important to consider pharmacological aids to help 
alleviate post-operative pain.   
 Ibuprofen is the prototypical Non-steroidal anti-inflammatory 
drug (NSAID) and represents the gold standard against which new 
analgesic agents are evaluated (Huber and Terezhalmy 2006).  The 
analgesic mechanism of action common to NSAIDS such as Ibuprofen 
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and Naproxen is their capacity to limit hyperalgesia by inhibiting the 
activity of COX-1 and -2, and thereby the synthesis of inflammatory 
and hyperalgesic prostaglandins within the peripheral tissues 
(Mehrvarzfar et al 2012). The inhibition of both COX-1 and COX-2 
reduces inflammation and pain by blocking the previously discussed 
mechanisms, and also inhibits activation of the transcription factor nu-
clear factor-kappa Beta (NF-Ƙß), which is critical for the inducible ex-
pression of multiple cellular and viral genes involved in inflammation 
and infection, including Interleukins -1 and -6 (IL-1, -6), and adhesion 
molecules (Kopp and Ghosh 1994).  
 However, COX-1 also have protective actions in the body 
which are also inhibited when taking NSAIDs.  Most NSAIDs devel-
oped are nonselective COX inhibitors, meaning that they block both 
COX-1 and COX-2 (e.g. Diclofenac, Diflunisal, Ketorolac, Naproxen, 
and Ibuprofen).  Non-assertive NSAID’s have been introduced as se-
lective COX-2 inhibitors; these include Celecoxib, Valdecoxib, and the 
recently discontinued Rofecoxib.  The selective COX-2 inhibitors 
block production of the inducible COX-2 products and their deleterious 
effects, while avoiding the unwanted side effects of COX-1 inhibition 
such as gastro-intestinal bleeding (Vane and Botting 1998).  Michels et 
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al in 2012 found the relative risk of any GI bleeding-related event 
ranged from 1.1 to 2.4% for users of over the counter Ibuprofen.  No 
studies have demonstrated that COX -2 inhibitors had better pain con-
trol compared to non-selective NSAIDs, however, it has been shown 
that COX-2 specific inhibitors will have a longer duration of action 
(Huber and Terezhalmy 2006).  It is important to note that the actions 
of lipooxygenase are not inhibited by COX-2 selective NSAIDs, and 
can only be limited via steroid intervention by the inhibition of the en-
zyme phospholipase A2 (Becker 2005).  COX -2 inhibitors have been 
shown to increase the risk for cardiovascular events in atherosclerotic 
arteries, as more Thromboxane A2 is produced, which promotes 
platelet-dependent thrombosis (Becker 2005).  A study which com-
pared patients taking selective COX-2, rofecoxib, versus a non-selec-
tive COX Naproxen for 6 weeks showed people on the rofecoxib had 
elevated blood pressure (Sowers et al 2005).  
 The non-selective NSAID ibuprofen was originally approved 
for prescription in 1974 with the brand name Motrin.  It was approved 
for over the counter sales in 1984 with a lower daily recommended 
dosage compared to the prescription product (200 mg every 4-6 hours 
vs. 400-800 mg every 4-6 hours)  with a maximum daily dose of 
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3200mg (FDA Non-prescrption use of ibuprofen and the risks of gas-
trointestinal and renal toxicity 2002).  The time of maximum plasma 
concentration for ibuprofen is 0.5-3 hours, with an elimination half-life 
of 2-3 hours (drugs.com).  Naproxen was originally marketed as the 
prescription only drug Naprosyn in 1976, while Naproxen sodium was 
marketed under the name Anaprox in 1980.  In the United States, the 
FDA approved its use as an over the counter drug in 1994, usually 
marketed under various names such as Aleve, Anaprox, Flanax, Proxen 
and Xenobid.  It is available in 250mg to 500mgdoses as Naproxen or 
275mg to 550mg for Naproxen sodium (250-550 mg twice per day) 
with a maximum daily some of 1500mg naproxen, or 1650 mg naprox-
en sodium (drugs.com).   The maximum placental concentration of 
naproxen is between 3-6 hours, with an elimination half life between 
12 - 17 hours (drugs.com).   
   '33
 
 
Figure 4: Where NSAID’s and COX-2 inhibitors interact in the eoicasanoid Syn-
thetic Pathway  
 Ibuprofen has been shown in numerous studies to be effective in 
relieving moderate dental pain.  Ibuprofen 400 mg has been shown to 
be superior to placebo four hours after third-molar-impaction surgery 
(Cooper et al, 1982).  The same dosage of ibuprofen has also been 
shown to be more effective than placebo and acetaminophen 1000 mg 
following other procedures including extractions, root end resections, 
biopsy, and deep gingival curettage (Mehlisch 2002).  Dionne found 
that the efficacy of 400 mg ibuprofen in controlling pain following re-
moval of 2-4 impacted third molars was not improved by the addition 
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of 5 mg of the opioid oxycodone (Dionne, 1999).   Naproxen has also 
shown it’s efficacy in relieving moderate pain post third-molar-im-
paction surgery, at a dose of 220mg  to 440mg for up to at least 8 hours 
(Young et al 2013, Li-Wan-Po et al 2013, Moore et al 2011).  It has 
been suggested that there are gender differences in analgesia effects of 
certain medications, especially in the Naloxone class where females 
have been shown to have greater analgesia than males over longer pe-
riods of time (Ryan et al 2008).   
 Acetaminophen is one of the most popular analgesics and an-
tipyretic agents in the United States (Guggenheimer 2011).  It has been 
proven to be an effective analgesic, but lacks the anti-inflammatory and 
anti-platelet effects and gastric irritation common with non-steroidal 
anti-inflammatory drugs (NSAIDs).  It is the only drug in the aniline 
family that is available in the United States (Aminoshariae and Khan 
2015).  For many decades, the mechanisms of action of acetaminophen 
were unclear.  It is now known that acetaminophen will block 
prostaglandin synthesis from arachidonic acid by inhibiting the en-
zymes COX-1 and -2 when the levels of arachidonic acid and peroxide 
are low, but have little effect when these levels are high, as seen in se-
vere inflammatory conditions (Aminoshariae and Khan, 2015).  Ac-
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etaminophen acts centrally and peripherally by inhibiting PGE2 syn-
thesis.  Unlike NSAIDs, acetaminophen also inhibits myeloperoxidase, 
and may slow the development of disease such as rheumatic disease 
and artherosclerosis.  Acetaminophen also has an antinociceptive effect 
linked to endogenous opioid, serotonin and cannabinoid neurotransmit-
ter systems.  Inhibitors of endogenous opioids, serotonin and cannabi-
noids will attenuate the antinociceptive effect of acetaminophen (Lee et 
al, 2007, Dani et al, 2007, Pelissier et al, 1996).  This effect of aceta-
minophen may also be mediated by inhibition of neurotransmitters in 
the central nervous system by attenuating the nociceptive behaviour of 
NMDA and SP (Aminoshariae and Khan, 2015).  Acetaminophen is 
absorbed in the small intestine, thus it is influenced by rate of gastric 
emptying and contents.  It has excellent bioavailability, reaching peak 
plasma concentration within thirty to sixty minutes.  Due to low plasma 
protein binding, it is readily distributed throughout the body 
(McGilveray, 1972).  It is also able to cross both the blood-brain barrier 
and placental barrier.  The maximum plasma concentration of Aceta-
minophen is between 0.5-3 hours, with an elimination half-life of 2-3 
hours (drugs.com).   
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 Acetaminophen is metabolized in the liver, producing a highly 
reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), where it 
is eliminated in urine.  After large doses of acetaminophen have been 
taken or when the patient has existing liver damage, alcohol issues, 
taking other medications metabolized in liver, or malnutrition, NAPQI 
may accumulate in the liver in high concentrations, resulting in hepatic 
damage even with therapeutic doses (Forrest JA, et al 1982, FDA drug 
safety communication, 2014).  Acetaminophen is the leading cause of 
acute liver failure in the United States, being the cause of nearly 50% 
of unintentional overdose (FDA drug safety communication, 2014).  To 
address these issues, the FDA centre for drug evaluation and research 
prepared an internal report that first changed labelling on over the 
counter packaging in 2009, which then led to manufactures limiting the 
strength of acetaminophen to a maximum of 325 mg per capsule in 
2011.  In January 2014 the FDA and manufacturers began to discontin-
ue prescribing and dispensing prescription combination drug products 
with more than 325 mg acetaminophen until ultimately they were all 
formally removed from market in March 2014 (FDA drug safety com-
munication, 2014).   
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 Despite the dangers of hepatotoxicity, acetaminophen is still 
used routinely because of the rarity of adverse effects on health, con-
currently used medications and laboratory tests.  Systemic reviews and 
meta-analysis have shown evidence that acetaminophen offers accept-
able analgesia that lasts for four hours with minimal effects for acute 
postoperative pain (Zahrowski, 2011, Barden et al, 2004).  Although it 
is not as effective in relieving acute pain as NSAIDs, it has been shown 
to provide effective analgesia in about 50% of patients with acute post-
operative pain, and is the analgesic of choice when NSAIDs are con-
traindicated (Zahrowski, 2011). 
 Narcotic analgesics are a class of analgesics that are useful in 
treating moderate to severe pain not alleviated by NSAIDs or aceta-
monophen.  Frequently used narcotic analgesics include morphine, hy-
drocodone, oxycodone, codeine, and meperidine.  Hydrocodone and 
oxycodone are semi-synthetic opioids with multiple actions qualitative-
ly similar to those of morphine.  Codeine and morphine occur naturally 
as a component of the poppy plant and can be recovered from the opi-
um extract of the plant.  These analgesics all bind and activate the mu 
(µ) opiate receptor in the CNS, as does the endogenous opiate beta-en-
dorphin (Hargreaves et al 1987).  Opioid receptor types include the mu 
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(µ), delta (δ), kappa (κ), and sigma (σ) receptors which inhibit adenylyl 
cyclases, increase intracellular calcium levels, decrease calcium cur-
rents, increase potassium currents, and regulate mitogen-activated pro-
tein (MAP) kinase second messenger cascade.  These actions inhibit 
neurotransmitter (e.g., SP) release and/or hyper-polarize cell mem-
branes, thus inhibiting neuronal activity (Law et al 2000). 
 Narcotic analgesics are selective for different opioid receptors 
and have different activity when bound to these receptors.  Activation 
of the µ receptor produces analgesia, respiratory depression, nausea, 
sedation, and addiction.  Activation of the δ receptor produces analge-
sia while activation of the κ receptor produces analgesia and sedation.  
The δ receptor, which has not been associated with an endogenous opi-
oid, is thought to produce immune system modulation, dizziness, light 
headedness, sedation, dysphoria, and psychotomimetic events such as 
hallucinations.  Morphine, hydrocodone, oxycodone, codeine, and 
meperidine are full µ receptor agonists, partial δ and κ receptor ago-
nists (Swift and Hargreaves 1993).  Certain brand medications such as 
Vicoprofen, Lortab ASA, and Empirin combine the NSAIDs ibuprofen 
and aspirin with a narcotic.  The effects of an anti-inflammatory agent 
combined with an analgesic drug working via different mechanisms 
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proving beneficial in the management of pain.  The maximum plasma 
concentration of hydrocodone is 1 to 1.5 hours, with an elimination 
half-life of 3-4 hours (drugs.com). 
 The number of studies on the efficacy of NSAIDS using an en-
dodontic model is limited (Holstein et al 2002).  Rogers found that 
post-instrumentation pain was consistently lower in patients given one 
600 mg dose of ibuprofen immediately post-treatment compared to 
placebo at 6, 12, 24, and 48 hours, but these differences were not statis-
tically significant (Rogers et al 1999).  Another study conducted by 
Torabinejad showed that 400 mg ibuprofen was more effective than 
placebo in treating postoperative endodontic pain following complete 
instrumentation.  The same study showed that acetaminophen 650 mg, 
aspirin 650 mg, and Phenaphen #4 (acetaminophen 325 mg + codeine 
60 mg) were not more effective than placebo (Torabinejad et al 1994).  
Menhinick’s study showed that a combination of ibuprofen and aceta-
minophen reduced pain 8 hours post operatively compared to ibuprofen 
alone and or placebo (Menhenick et al 2004).  In a study done by 
Doroschak conducted at the University of Minnesota, patients treated 
with fluriprofen and Tramadol reported less pain compared with the 
placebo group, showing an NSAID/opiate combination in conjunction 
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with endodontic therapy may be useful in the management of endodon-
tic pain (Doroshak et al 1999). 
 Extraction of impacted third molars serves as the standard mod-
el for testing efficacy of analgesics on dental pain.  This model induces 
pain that is consistent in severity, which allows discrimination between 
weak and strong analgesics (Urquhart 1994, Ryan et al 2008), and pro-
vides the U.S. Food and Drug Administration with accepted evalua-
tions of analgesic therapies (Averbuch and Katzper 2000).  However, 
the oral surgery model does have limitations.  Demographically, it 
tends to enlist a young, healthy, homogenous population seeking elec-
tive surgery.  It also tests pain of fairly limited range and duration 
(Mehlisch 2002).  The oral surgery model is also based on acute in-
flammation following a healthy state.  In contrast, the endodontic mod-
el differs in that patients seeking endodontic treatment vary in age, 
health status, and preoperative pain presentation.  The endodontic 
model also includes acute inflammatory states following treatment of 
chronic or acute inflammation.    
 Pain is a complex perception, having both a sensory and emo-
tional component to it, thus it’s measurement can be quite problematic 
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(Chapman et al 1985).  The progress in the measurement in pain has 
been slow due to the fact that pain is a complex perceptual experience 
that can be quantified only indirectly.  Some of the methods used to 
quantify pain in clinical research are rating scales(Joyce et al 1975, 
Chapman et al 1985).  One type of rating scale is called category 
judgment, where subjects are given a structured categorized scale that 
represent pain intensity and asked to rate each stimulus on that scale 
(Chapman et al, 1985).  A scale designed by Frank et al introduced a 
category rating scale that involved 8 cartoon faces with varied expres-
sions, from laughter to total misery.  The picture selection scores corre-
lated well with responses made on a 5-point rating scale (Frank et al, 
1982).  The visual analogue scale (VAS) is another type of rating scale 
where subjects are told to indicate the intensity of pain by marking a 
100 mm line that is labeled ‘no pain’ at one went and ‘the worst pain 
possible’ at the other (Joyce et al 1975).  The patient will mark on the 
line where they perceive their pain, and then the pain intensity scores 
are calculated by measuring the distance from the left end point to the 
mark (Joyce et al 1975, Cohen et al 2008).  Advantages to VAS include 
the ease of administration and understanding by the subjects, low cost, 
and ratio data (Cohen et al 2008).   
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 The VAS is the gold standard for measuring pain in emergency 
medicine (Holdgate et al 2003).  The Heft-Parker scale incorporates the 
patients common understanding of six pain descriptive words that are 
irregularly spaced on a 170mm horizontal line (Heft and Parker 1984).  
It is though that the patient will make category judgements on the basis 
of word meanings and that categorical rating are not merely an ordinal 
reading.   Categorical scales are simply descriptive of the pain intensity 
on a four point scale from “no pain” to “severe pain”.  Despite the sim-
plicity of this scale, they have consistently been shown to be a reliable, 
comparable and repoducible measure for clinical pain trials (Averbuch 
and Katzper 2004). 
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RESULTS: 
 Few patients met the clinical criteria established for this study, 
with 29 patients enrolled (13 females and 16 males).  Unfortunately, six 
patients failed to return their completed forms (5 males, and 1 female), 
providing data for 22 patients.  Three pain measurement scales were 
used to analyze patient pain levels; VAS, HP and categorical.  The Cat-
egorical scale was measured with 0 being no pain, 1 being mild pain, 2 
being moderate pain, and finally 3 being severe pain.  An example of 
the pain diary can be found in Appendix 3.  All patients were seen be-
tween 2:00 and 4:00 PM during the graduate endodontic clinic emer-
gency time.  The three pain scales corresponded well with each other, 
and showed similar trends of each medication over the time periods. 
 The comparability between the four medication groups was an-
alyzed according to patient characteristics such as age, gender, and pre-
senting pain according to the VAS, Heft Parker and categorical reading.  
This is summarized in Table 1 below.     
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Table 1: Patient Baseline Characteristics based on gender 
  
 We then evaluated the comparability among the four medication 
groups for distribution of preoperative pulpal diagnosis (Table 2), api-
cal diagnosis (Table 3), and tooth type (Table 4).  The group with the 
initial dose of Ibuprofen followed by a second dose of Vicodin had 
more previously treated teeth compared to the other groups.  The 
Naproxen group had no previously treated teeth in its’ group.   Ibupro-
fen and placebo groups also showed more cases with acute apical ab-
scess compared with the other groups.  Because our numbers were so 
low, this is one of the inevitable downfalls. 
Gender N Mean Age Mean 
Initial 
VAS (mm)
Mean 
Initial HP 
(mm)
Mean Initial
Categorical
Males 16 40.69 60.05 104.3 2.3
Females 13 36.23 52.9 94.75 2.25
COMBINED 29 39.84 56.14 99.1 2.25
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Table 2: Distribution of pulpal diagnosis among the medication groups 
Table 3: Distribution of apical diagnosis among the medication groups 
Medication Type Total N Necrotic SIRP Previously 
Treated
Placebo 6 2 3 1
Ibuprofen 4 1 2 1
Ibuprofen then 
Hydrocodone/
ACA
6 0 3 3
Naproxen 6 4 2 0
Medication 
Type
Total N Normal SAP AAA
Placebo 6 0 4 2
Ibuprofen 4 0 1 3
Ibuprofen then 
Hydrocodone/
ACA
6 0 6 0
Naproxen 6 0 5 1
Medication 
Type
Total N Anterior Premolar Molar
Placebo 6 2 0 4
Ibuprofen 4 1 3
   '46
Table 4: Distribution of tooth type among medication groups 
 We took readings of the patients perceived pain prior to initia-
tion of root canal therapy, immediately after the first stage of root canal 
was carried out.  The patients then took the pain diary home, and filled 
in the three pain scales at the following time intervals; 1 and 4 hours 
after taking dose #1 of medication, 1 hour after taking dose #2 of med-
ication, then the following day at breakfast, lunch, dinner and bedtime. 
'  
Ibuprofen then 
Hydrocodone/
ACA
6 0 0 6
Naproxen 6 0 0 6
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Figure 6: Graphical representation of Heft Parker readings at various time 
points for the various medication groups: Placebo (HP P), Naproxen (HP N), 
Ibuprofen (HP I), and Ibuprofen, followed by a dose of Vicodin (HP V). N=22 
with Standard error bars shown
!
Figure 7: Graphical representation of categorical pain readings at various time 
points for the various medication groups: Placebo (CAT P), Naproxen (CAT N), 
Ibuprofen (CAT I), and Ibuprofen, followed by a dose of Vicodin (CAT V). N=22 
with Standard error bars shown 
Table 5: The change in VAS reading at each time point based on medication.  A 
higher number corresponds to a greater reduction in pain. 
Initial-
pain 
(mm)
Imm 
Post
1hr 
after
dose 
#1
1hr 
after 
dose 
#2
Next 
day
Break-
fast
Next 
day
Lunch
Next 
day
Dinner
Next 
day
Bed
Place
bo
51.75 41.75 29.42 22.83 36.17 31.58 36.92 36.50
Napro
xen
56.17 38.83 37.20 50.17 37.83 39.50 39.75 48.17
Ibupro
fen
59.75 42.88 52.88 47.88 46.13 35.13 39.40 47.13
IBU
+VIC
58.10 50.58 38.00 44.92 34.75 44.33 43.83 47.25
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Figure 8: Graphical representation showing changes in VAS measurements 
(mm) at each time point for each medication.  A logarithmic calculation is super-
imposed over the readings.  Least reduction in pain noted in placebo group.  All 
medication groups show similar reduction in pain at all-time points after the 
second dose 
  
 The VAS and HP showed the greatest reduction of pain imme-
diately post op for all groups of medication except Ibuprofen (Figures 
4 and 5).  The placebo group showed an increase in pain an hour after 
its first dose, rebounding to a reading close to the preoperative pain 
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levels an hour after the second dose.  However, the pain decreased the 
following day, increasing only slightly at the final reading “Day 2 bed-
time”.   The ibuprofen reached its lowest level of pain on the VAS and 
HP at one hour after the second dose of the medication.  This group 
showed the highest level of rebound, to levels close to the preoperative 
pain according to the VAS scale, and even higher than the initial pain 
on the HP and categorical scales.  The Ibuprofen and Vicodin group 
rebounded slightly one hour after taking the first dose from its mini-
mum immediately post operatively, then decreased again one hour after 
the second dose.  This group continued to decrease the following day, 
and did not see the same rebound as the Ibuprofen group.  The Naprox-
en group had the lowest levels of pain on both the VAS and HP scales, 
decreasing further once the placebo pill was taken, roughly 7 hours af-
ter the Anaprox DS was taken.  This trend continued the following day.  
The VAS scores were used to calculate the reduction in pain at each 
time point.  This showed the least reduction in pain in the placebo 
group at all time intervals.  Ibuprofen had the highest reduction in pain 
at the one hour following the first dose of medication mark.  At all time 
intervals, the medicated groups were very similar (Table 5, and Figure 
7).   
   '50
 Next, we analyzed if gender had any effect on postoperative 
pain and success of analgesic medication.  Results can be found in fig-
ures 8, 9, 10 and 11 that follow: 
'
' '  
Figure 9: (From top clock-wise) VAS, categorical scale and HP pain readings at 
various time points for Placebo medication, where the blue line represents males 
and the pink, females. N=22 with Standard error bars shown 
 Figure 9 showed that males have a greater rebound in pain 
compared to females, with pain levels rebounding to preoperative lev-
   '51
els an hour after the second placebo dose was taken.  The pain levels 
generally decreased the following day for both genders, however, the 
pain remained higher for the male group.  Females showed better pain 
relief at later time intervals compared to men in both the HP and cate-
gorical scaled.   
'  
'  '  
Figure 10: (From top clock-wise) VAS, categorical scale and HP pain readings at 
various time points for Ibuprofen medication, where the blue line represents 
males and the pink, females. N=22 with Standard error bars shown 
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 Figure 10 showed that ibuprofen showed the lowest levels of 
pain for males one hour after the first dose was taken, and the lowest 
level of pain for females one hour after the second dose.  Both males 
and females had a rebound of pain the following day to preoperative 
pain ranges.  Males had better pain relief compared to females with this 
medication.  
'  
'  '  
Figure 11: (From top clock-wise) VAS, categorical scale and HP pain readings at 
various time points for Vicodin and Ibuprofen medication, where the blue line 
represents males and the pink, females.  N=22 with Standard error bars shown 
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 Figure 11 above shows a similar decrease in pain levels for both 
the male and female groups once the ibuprofen and Vicodin combina-
tion were taken.  There was a slight rebound in pain noted in the morn-
ing after for the male group, however, the pain levels decreased abrupt-
ly again, following a similar trend as the female group.  Males had 
slightly more pain relief, especially at later time interval. 
'
'  '  
Figure 12: (From top clock-wise) VAS, categorical scale and HP pain readings at 
various time points for Naproxen medication, where the blue line represents 
males, and the pink females.  N=22 with Standard error bars shown 
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 Figure 12 shows a similar decrease in pain for both the male 
and female groups at all time intervals after the first dose of Anaprox 
was taken.  This decrease in pain level continues for both male and fe-
males after the placebo dose was taken a few hours later.  There was a 
slight rebound in pain noted the second day in the male group, while 
the female group continued to have decreased pain.  Females had more 
relief at later time intervals for men in the Anaprox group.  Finally, we 
analyzed whether or not the pulpal vitality played a role in post opera-
tive pain, and if this relationship was influenced by medication type.   
'  '  
'  '  
Figure 13: From top left clock wise; VAS scales of Placebo, Ibuprofen, 
Vicodin+Ibuprofen and Anaprox for vital pulps (L) and necrotic pulps 
(D). N=22 with Standard error bars shown 
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 Figure 13 suggests that postoperative pain depends on pulp vi-
tality.  In the placebo group there was a similar decrease in pain inten-
sity noted between both the vital and necrotic teeth. A slight rebound in 
pain postoperatively an hour after the second medication was taken 
was noted in the vital teeth compared to necrotic.  In the Ibuprofen 
group, there was a sharp decrease in pain following postoperative 
treatment in the vital teeth, while the necrotic teeth showed quite a re-
bound of pain greater than the initial pain the following day.  There 
was no such rebound noted in the Ibuprofen and Vicodin group, how-
ever, there was slightly more postoperative pain in the necrotic tooth 
during the first day after treatment.  This pain decreased to a negligible 
level the following day in this group.  Finally, the Naproxen group 
showed a sharp decline in pain postoperatively, which remained at low 
levels for the duration of the measurements.  The necrotic group had 
slightly higher pain levels during the second day.   
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DISCUSSION: 
 Even when endodontic procedures are performed to the highest 
standard, the literature has shown that patients can suffer with postop-
erative pain up to 40% of the time, especially during the first 24 hours 
(Harrison et al 1983, Moskow et al 1984, Georgopoulou et al 1986, 
Oguntebi et al1992, Liesinger et al 1993, Marshall and Liesinger 1993, 
Torabinejad et al 1994, Mattscheck et al 2001, Direnzo et al 2002).  We 
had similar findings in our study.  If one considers a 10mm or less 
reading on the VAS scale as mild pain, then about 63% were pain free 
at the ‘lunch time’ reading, (which roughly corresponds with 24 hours 
post operative) while 86% of our patient population were without pain 
at the final reading (about 36 hours post op).  If one considers a reading 
between 30 mm and 50 mm moderate pain, then about about 14% of 
our patients had moderate pain at the 24 hour mark and about 23% at 
the 36 hour reading and.  Finally, If one considers greater than a 50 mm 
reading on the VAS as severe pain, then 14% of the patients in our 
study had severe pain at the ‘lunch time’ reading  and none at the final 
reading.   The VAS readings corresponded well with the categorical 
scale.   
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 The literature has also shown that pain is usually proportional to 
the severity of the inflammatory event which occurs in response to 
periradicular tissue trauma (Siqueira 2003).  The best predictor of post-
treatment endodontic pain is the severity of the pre-treatment pain 
(O’Keefe 1976, Harrison et al 1983, Marshall and Walton 1984, Tora-
binejad et al 1988, Mattscheck et al 2001).  This was also found in our 
study, with patients presenting with the highest VAS preoperative pain 
having the highest post operative pain.  Pharmaceutical aids in the way 
of analgesic agents or a combination of anti-inflammatory/analgesic 
agents can be used to control post-treatment pain.  The type of pharma-
ceutical aid utilized has classically depended on the severity of the 
pain.  NSAIDs such as ibuprofen have been shown to adequately man-
age mild to moderate dental pin (Cooper et al 1982, Mehlisch 2002).  
Moderate to severe pain is better managed with the addition of a nar-
cotic agent such as hydrocodone to an NSAID (Hargreaves 1997,  
Dionne et al 1999).   
 The majority of the dental analgesic studies have been limited 
to the oral surgery model  (Averbuch and Katzper 2000).  Demographi-
cally, these studies tend to include a young, healthy, homogenous popu-
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lation seeking elective surgery.  These patients are usually free of acute 
or chronic inflammation prior to treatment (Mehlisch 2002, Ryan et al 
2008).  In contrast, the endodontic model utilized in our study differs in 
that patients varied in age, health status, and preoperative pain presen-
tation.  The endodontic model also includes acute inflammatory states 
following treatment of chronic or acute inflammation (Ryan et al 
2008).  This mean there will likely be an accumulation of inflammatory 
cells and cell mediators such as bradykinin, histamine and oxidation 
products of arachidonic acid.   All of these will lead to the synthesis of 
prostaglandins and other active substances, which will lead to hyperal-
gesia (Hargreaves et al 2001).  The average age of patients who partic-
ipated in our study was 39.84, with  an average VAS and Heft-Parker 
readings of 56.14/100 and 99.1/170 respectfully (Table 1).   
 In this study, only 22 patients met the inclusion criteria and 
completed their at home pain diary.  Participation in the study was lim-
ited to patients experiencing pre-treatment pain of 30mm or higher on 
the VAS, as they would be most likely to experience post treatment 
pain (O’Keef 1976).  Among the other inclusion criteria mentioned in 
the material and methods section, the participating patients were not to 
have taken any form of analgesic four hours prior to their appointment.  
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This was the factor that proved to be the greatest barrier to getting par-
ticipants, as the majority of the emergency patients had taken some 
form of analgesic prior to their appointment.  All graduate endodontic 
emergency appointments offered at the University of Minnesota are in 
the afternoon, thus it is very likely that the patient would have taken 
some form of analgesic to get through the morning.  Moreover, there 
were unfortunate time constrains that also limited the number of pa-
tients we could recruit.  An increase in sample size would have defi-
nitely been more beneficial as it would have made the spread of pulpal 
and apical diagnosis and tooth time more evenly distributed (Tables 
1-4).  The original estimation of a statistically significant sample size 
was calculated to be around 120 patients.  
 Either 0.5% Bupivicaine (1:200000 epi) or 2% lidocaine 
(1:100000 epi) was given, and initial root canal therapy was carried out 
by a resident endodontist.  There were four different operators used in 
an effort to increase the sample size and help recruit patients.  All oper-
ators were residents and used the modified crown-down technique pri-
marily with the use of rotary instrumentation.  This is due to the fact 
that there would be less debris extruded apically and thus, and de-
creased chance of inflammatory response and postoperative pain (Ruiz-
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Hubard et al 1987, Reddy and Hicks 1998).  Sodium hypochlorite was 
used for irrigation as it is the most effective irrigant, and its use has 
been shown to decrease post operative pain when compared to saline 
(Harrison et al 1983).  Calcium hydroxide was placed into a canal with 
a cannula to aid in the elimination of bacterial which may survive bio-
mechanics instrumentation (Sjogren et al 1991).  After the treatment 
was carried out, patients were administered one of the following regi-
men; 1)  Placebo for both doses, 2)  Anaprox DS (550mg Naproxyn 
sodium) 1st dose, Placebo 2nd dose; 3)  Ibuprofen 800mg 1st dose, 
Ibuprofen 800 mg 2nd dose; and finally 4)  Ibuprofen 800 mg + Vicodin 
(acetaminophen/hydrocodone) 1st dose, Ibuprofen 800 mg + Vicodin 
2nd dose.  These medications were taken when the patient got home 
after treatment, and then again at a 6-hour interval.  Patients reported 
pain levels using categorical, VAS and Heft-Parker pain scales one 
hour after taking each dose of medication, and then the following day 
at breakfast, lunch, dinner and before bedtime.   
 There is evidence found in the literature to support the fact that 
administration of an analgesic drug will decrease post operative pain.  
Acetaminophen alone has been a useful medication that effectively 
lowers pain intensity in most patients, with the advantage that it it does 
   '61
not irritate the stomach and intestinal lining  (Guggenheimer and 
Moore 2011, Kraglund 2014).  Acetaminophen acts by inhibiting 
prostaglandin synthesis in the CNS and by interacting with serotonin 
and nitric oxide mechanisms (Bjorkman 1995).  It is able to cross the 
blood-brain barrier which will allow inhibition of central hyperalgesia 
produced by neurotransmitters such as substance P (Bjorkman 1995, 
Aminoshariae and Khan 2011).  Acetaminophen, however, has a nar-
rower window of safety compared with NSAIDs. It’s byproduct 
NAPQI may accumulate in the liver resulting in hepatic damage (For-
rest JA et al 1982, FDA drug safety communication 2014).  Because of 
differing mechanisms and sites of action, acetaminophen can be used in 
combination with either an NSAID or an opioid such as hydrocodone 
to increase it’s analgesic effect, as well as decrease the dose of Aceta-
minophen needed (Kraglund 2014, Menhinick et al 2004, Guggen-
heimer and Moore 2011).  
 Narcotic analgesics are a class of analgesics that are useful in 
treating moderate to severe pain not alleviated by NSAIDs or aceta-
monophen.  Hydrocodone was utilized in this study and is a semi-syn-
thetic opioids with multiple actions qualitatively similar to those of 
morphine.  It’s mechanism of action is that it will bind and activate the 
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mu (µ) opiate receptor in the CNS, as does the endogenous opiate beta-
endorphin (Hargreaves et al 1987).  These actions inhibit neurotrans-
mitter (e.g., SP) release and/or hyper-polarize cell membranes, thus 
inhibiting neuronal activity (Law et al 2000).  Vicodin which consists 
of 325 mg of Acetaminophen and 7.5 mg Hydrocodone was taken with 
800mg Ibuprofen.  This study used the NSAIDs Ibuprofen and 
Naproxen.  These drugs inhibit prostaglandin synthesis by decreasing 
the activity of cyclo-oxygenase enzyme (COX), which is released with 
tissue injury and detected in high concentrations in macrophages, 
monocytes, leukocytes in response to mediators of inflammation 
(Cooper et al 1993, Arslan et al 2011).  This class of drug is associated 
with a dose-dependent risks, such as the development of serious gas-
trointestinal bleeding (Vane and Botting 1998).   Ibuprofen, which is 
one of the most commonly used NSAID (Menhinick et al 2004, Cooper 
et al 1993) and was utilized in our study at two high doses of 800 mg 
each.  Anaprox DS (550 mg Naproxen) has improved absorption char-
acteristics, and longer plasma levels compared to Ibuprofen (Young et 
al 2013).  This drug has the benefit of needing fewer doses which car-
ries fewer risks long term. 
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 There were no untoward events through the study, and no pa-
tients required additional analgesic intervention.  In the literature, the 
incidence of complications due to NSAIDs is between 1.1 to 2.4 %, 
with the majority of issues being gastric bleeding (Michels et al 2012).  
All patients participating in this study showed a decrease in pain level 
immediately following initial root canal therapy.  The pain level rose 
again in all groups at the next time point which one would expect as 
this would correspond with the local anaesthetic wearing off (Malamed 
1990).  Again, there were two types of local anaesthetic used in our 
study, thus this should be considered when analyzing the data.  It has 
been shown that long acting anaesthesia such as 0.5% bupivacaine will 
have a significant decrease in postoperative pain compared with 2% 
lidocaine (Dionne et al 1999, Moore and Dunsky 1983).  The effects of 
these local anaesthetics were looked at in another study.   
 The placebo group showed a significant decrease in pain when 
comparing the initial pain levels, which suggests that definitive treat-
ment will decrease the pain intensity.  This finding is consistent with 
the literature (Doroschak et al 1999, Menhinick et al 2004).   The 
placebo effect is another possibility for this finding.   A greater de-
crease in postoperative pain was seen in the medication groups when 
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compared to the placebo group at later time periods with the exception 
for Ibuprofen (Figures 4, 5, 6).  The Ibuprofen group had it’s lowest 
levels of pain one hour after the medication was given, however, there 
was a rebound in pain to levels  near the initial pain during the second 
day, with a maximum reading of pain occurring at lunch time.  Studies 
have shown that taking a single dose of oral ibuprofen can augment 
concentrations of circulating pro inflammatory cytokines, such as TNF, 
IL1 and elastases (Pinas et al 1991).  Using stimulated peripheral blood 
mononuclear cells, Endres et al also found an increase in TNF, IL1 al-
pha and beta synthesis in subjects who had taken Ibuprofen.  There 
were parallel increases in PGE2 also observed in this group.  The con-
clusion was made that there is a ‘rebound’ increase in cytokine-induced 
cytokine synthesis in groups that had taken 200mg of Ibuprofen for 2 
weeks, at 12 days after discontinuing this dose (Endres et al 1996).  
This is a plausible cause of the rebound in pain after the high 1600 mg 
dose taken the day prior.  Patients were also likely taking Ibuprofen in 
the days leading up to the dental appointment.   
 The rebound in pain was not noted in the 800 mg Ibuprofen and 
Vicodin group (Figures 4, 5, 6).  Vicodin is composed of 7.5 mg of 
Hydrocodone and 325mg Acetaminophen, and has the benefit of com-
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bining the u-agonist of the opioids with the central and peripheral inhi-
bition of PGE2 of the Acetaminophen.  These components work via 
different mechanisms proving beneficial in the management of pain.  
Menhenecks study showed that a combination of ibuprofen and aceta-
minophen had superior analgesia at 8 hours post operatively compared 
to ibuprofen alone and or placebo (Menhenick et al 2004). The litera-
ture has shown the addition of a small amount of opioids to NSAIDs 
can be quite beneficial, especially with moderate to severe pain 
(Dionne et al 2001, Litouwski et al 2005).  When prescribing these 
combination drugs such as Vicodin, it is important that the clinician 
plays particular attention to the amount of acetaminophen used, and 
that the maximum daily dose of 3 g is not exceeded due to dangers of 
liver damage (Guggenheimer 2012, Aminoshaire and Khan 2015).   
 The naproxen group showed the greatest reduction in pain com-
pared to all other groups at every time point after the medication was 
taken.  The initial pain levels were similar when comparing to the other 
groups (Figure 4, 5, 6).  Doses between 200 and 400 mg have shown to 
be effective for analgesia over a 12 hour time period in the literature 
(Young et al 2013, Li-Wan-Po et al 2013).  These findings are expected 
when you consider the pharmacodynamics of these medications.  
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Ibuprofen will reach it’s maximum plasma concentration between 0.5 
to 3 hours with an elimination half life between 2 to 3 hours, while 
Naproxen's maximum plasma concentration is reached between 1-3 
hours, with an elimination half life between 12 to 17 hours 
(drugs.com).  Anaprox DS has enteric-coating that is designed to pro-
tect your stomach, and offer extended release of medicine.   
 Males and females had similar post operative pain.  When ana-
lyzing the results of the placebo group (Figure 8), it is noted that the 
male group had a rebound in pain similar to the preoperative pain one 
hour after the second dose of placebo was given.  The following day 
showed a continuation of slightly elevated postoperative pain com-
pared to females.  This contradicts the literature which concludes that 
female gender is normally a red flag for the possibility of post opera-
tive flare-ups (Torabinejad et al 1988, Ng et al 2004, Polycarpou et al 
2005).  Other literature that found gender has no effect on the preva-
lence of post operative pain suggested that those studies that did were 
biased as females were more likely to seek treatment even for mild 
pain (Locker and Grushka 1987, MacEntee et al 1993).  Among the 
patients taking 800mg Ibuprofen, both Males and females showed a 
dramatic rebound in pain on day two .  This rebound was more dramat-
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ic on the HP scale for females (Figure 9).  There were similar pain 
scale readings between the two genders for both the Ibuprofen and Vi-
codin group and Naproxen groups (Figures 10 and 11).  There was 
greater pain relief in the later time intervals among females in the 
Naproxen group compared to males, which would correspond with 
what the literature (Kshirsagar et al 2008, Ryan et al 2008). 
 Studies have been contradicting when considering preoperative 
tooth vitality as a factor, with some suggesting there is greater discom-
fort in necrotic teeth (Walton and Fouad 1992) and others suggesting 
that pulpal diagnosis has no significance, especially if apical patency is 
maintained (Arias et al 2009, Arias et al 2013).  The results obtained in 
this study were equally confounding, and varied between the placebo 
group and the Ibuprofen group.  In the placebo group there was a simi-
lar initial decrease in pain intensity noted between both the irreversible 
pulpitis (IRP) and necrotic teeth however there was more of a rebound 
postoperatively in the IRP teeth compared to necrotic (Figure 13).  This 
could be due to the up to 8-fold increase substance P levels in IRP tis-
sues (Bowles et al. 2003).  Prostaglandin are also present in higher 
concentrations in acutely inflamed teeth, thus increasing inflammation 
and discomfort (McNicholas et al. 1991).  Mechanical allodynia is 
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more common in teeth diagnosed as IRP compared to necrotic teeth (67 
vs 56% respectively) and can add to the post operative discomfort felt 
by the patient (Olgart et al 1989).  In the Ibuprofen group, there was a 
sharp decrease in pain following postoperative treatment in the IRP 
teeth, while the necrotic teeth showed quite a rebound of pain greater 
than the initial pain the following day. Perhaps this could be due to the 
rebound effect that can be seen with Ibuprofen discussed by Endres et 
al in 1996 and mentioned previously.  With necrotic teeth, there will 
likely be an accumulation of inflammatory cells, bradykinin, histamine 
and oxidation products of arachidonic acid due to the chronic nature of 
the disease.   These will lead to the synthesis of prostaglandins and 
other active substances, which will lead to hyperalgesia (Hargreaves et 
al 2001).  These chronic inflammatory products as well as bacteria can 
be extruded after instrumentation, thus leading to more post-operative 
pain (Seltzer and Naidorf 1985, Torabinejad et al 1988, Siqueira et al 
2004).  There was only negligible differences between the IRP and 
necrotic teeth in the Ibuprofen and Vicodin and Naproxen groups, both 
showing a sharp decline in pain postoperatively and remaining at low 
levels for the duration of the measurements.  
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 Categorical, VAS and Heft-Parker scales were filled in by the 
patients to indicate the pain felt at certain time intervals.  The quantifi-
cation of subject responses on categorical scales can be problematic as 
the categorization does imply rank ordering.  The category boundaries 
are not known and the approximation of the ranked categories to equal 
intervals is often assumed rather than demonstrated (Chapman et al 
1985).  Moreover, numbers were assigned to categories in order to ana-
lyze the data.  This is questionable unless the investigator has evidence 
that the subjects treat the categories like equally spaced numbers 
(Joyce et al 1975, Chapman et al 1985).  Heft Parker categories are not 
equally spaced, and these irregular spaces reflect differences in the 
meaning of the descriptors used on the scale.  VAS tend to be prefer-
able for clinical applications, as categorical scales may produce artifi-
cially augmented scores (Joyce et al 1975).  One issue with this scale, 
however, is that we are assuming that pain is a unidirectional experi-
ence which varies only in intensity.  Thus, these scales are liable to re-
sponse biases.  Broad ranges of psychological experiences are com-
pressed onto artificially small continuums.  Subjects will tend to spread 
responses over the entire scale regardless of magnitude of actual sensa-
tions (Chapman et al 1985).  
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 Further recruitment of patients using this model and analgesic 
combinations would be beneficial for the treatment and or prevention 
of post operative discomfort following endodontic treatment.  A sug-
gested change would be to recruit and treat patients in the morning, 
when they are less likely to have taken an analgesic. 
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Conclusion 
The outcome of this study suggests that primary endodontic treatment 
will greatly decrease the pain felt by the patient.  It is suggested from 
this study that high doses of Ibuprofen followed by abrupt stop can 
lead to a rebound in pain.  Anaprox DS shows a consistently lower pain 
score at longer time periods, with this being more marked for females.  
There was not much difference in post operative pain scores between 
men and women.  Tooth Vitality did not effect post operative pain.  
Due to low numbers of participants, the null hypothesis that there will 
be no difference between the various groups of analgesics for post op-
erative pain control can not be either accepted or rejected.  More re-
search using this model and analgesic combinations would be useful as 
the administration of definitive dental treatment with an appropriate 
analgesic or analgesic combination is important for the management of 
the patient with endodontic pain 
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